TargTex
Business Services · Portugal · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Avenida Tenente Valadim 2ºF No 17, Torre...Phone Number
+351 217904711Website
www.targtex.comRevenue
<$5 MillionIndustry
ZI Rank: 1
About TargTex
TargTex Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TargTex your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if TargTex has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if TargTex is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when TargTex launches new products
Funding: Get notified immidiatlly once TargTex has new funding data
Earning: See what the market has to say on TargTex recently announced quarterly report
Click to see if TargTex had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at TargTex
TargTex, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined TargTex as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
TargTex is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
TargTex is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about TargTex.
TargTex Tech Stack
A closer look at the technologies used by TargTex
Top Business Services Companies
Frequently Asked Questions Regarding TargTex
TargTex is focused on developing localized therapies for hard-to-treat tumors, particularly targeting glioblastoma. The company aims to create innovative treatments by aligning scientists, physicians, and patients, and has established collaborations with leading institutions globally. Their lead product, TTX101, has received orphan-drug designation... Read More
